Listen on the go
Feedback
We’d love to hear your feedback on this activity. It helps us to continually improve our products.
CORRECT!
Faculty & Disclosures
Dr Charles Daley
National Jewish Health and University of Colorado, Denver, CO, USA
Icahn School of Medicine at Mount Sinai, New York, NY, USA
Charles Daley is chief of the Division of Mycobacterial and Respiratory Infections at National Jewish Health (NJH) and professor of medicine at NJH, the University of Colorado, and Icahn School of Medicine at Mount Sinai. read more
Dr Daley has served on and chaired expert panels for the World Health Organization, Centers for Disease Control and Prevention, Infectious Diseases Society of America and American Thoracic Society. He has participated in multiple guideline panels for these organizations. He recently chaired the revision of the multi-society sponsored Non-tuberculous Mycobacterial Pulmonary Disease Treatment Guideline.
Dr Daley was awarded the World Lung Health Award by the American Thoracic Society for his work in multidrug-resistant tuberculosis. Dr Daley served as the inaugural chair of the Bronchiectasis Research Registry. He was previously associate editor of the American Journal of Respiratory and Critical Care Medicine and is currently associate editor of the European Respiratory Journal. His academic interests include tuberculosis global health policy and clinical and translational research related to tuberculosis, non-tuberculous mycobacterial infections and bronchiectasis.
Dr Charles Daley discloses: Advisory board or panel fees from AN2 Therapeutics, AstraZeneca, Insmed, Matinas, Paratek, Pfizer, Renovion and Spero. Consultancy fees from AN2 Therapeutics, Genentech, Paratek and Renovion. Grants/research support from AN2 Therapeutics, Bugworks, Insmed, Paratek and Renovion.
Prof. Stefano Aliberti
Humanitas University and Humanitas Research Hospital, Milan, Italy
Stefano Aliberti is professor of respiratory medicine at Humanitas University and director of the Respiratory Department at the Humanitas Research Hospital in Milan, Italy. He is also leading the bronchiectasis and non-tuberculous mycobacteria programmes at the Humanitas Research Hospital. read more
Prof. Aliberti has extensive experience in epidemiological and clinical research in pneumonia since the early 2000s when he was working for the Community-Acquired Pneumonia Organization at the Division of Infectious Diseases at the University of Louisville, KY, USA.Â
Over the past 15 years, Prof. Aliberti has been heavily involved in chronic respiratory infection research, including bronchiectasis and non-tuberculous mycobacteria, and received the Young Researcher Award in Respiratory Infections from the European Respiratory Society (ERS) for his contribution to community-acquired pneumonia. He founded the European Bronchiectasis Registry and is the chair of both the Italian Bronchiectasis Registry and the Italian Registry of Pulmonary Non-Tuberculous Mycobacteria. He is also chair of the ERS END-COVID clinical research collaboration. Prof. Aliberti has been an active member in different international societies over the past decade, including ERS, American College of Chest Physicians and the European Cystic Fibrosis Society. Prof. Aliberti has been involved in the development of guidelines on bronchiectasis, COVID-19 and severe pneumonia, as well as statements on tuberculosis. He is also associate editor (chest infections) for CHEST.Â
Prof. Aliberti’s major clinical and research interests are in both acute and chronic respiratory infections.
Prof. Stefano Aliberti discloses: Advisory board or panel fees from AstraZeneca UK Ltd (relationship terminated), Insmed, and Insmed Italy Srl (relationship terminated). Consultancy fees from Grifols Shared Services North America Inc., Fondazione Internazionale Menarini, Insmed Ireland Ltd, Insmed Italy Srl and Zambon Spa (relationships terminated with all companies). Grants/research support from Fisher & Paykel and Insmed. Speaker’s bureau fees from CSL Behring GmbH, GlaxoSmithKline SpA and Insmed Italy Srl (relationships terminated with all companies).
Dr Anne O’Donnell
Georgetown University, Washington, DC, USA
Anne O’Donnell is professor of medicine and the Nehemiah and Naomi Cohen chair in pulmonary disease research at Georgetown University Medical Center, Washington DC, USA. She is also the chief, Division of Pulmonary, Critical Care and Sleep Medicine. read more
Dr O’Donnell is board certified in pulmonary medicine, critical care, sleep medicine and internal medicine. Her clinical and research activities focus on the care of patients with non-cystic fibrosis bronchiectasis and related infections. She has a long track record of publications and leadership in clinical trials for bronchiectasis and associated infections.
Dr Anne O’Donnell discloses: Advisory board or panel fees from AstraZeneca, Boehringer Ingelheim, Electromed, Insmed, Paratek, Xellia (relationship terminated) and Zambon. Grants/research support from AstraZeneca, Insmed, Paratek, Redhill Biopharma and Zambon.
